{"filings":[{"id":68083,"accession_number":"0001156039-26-000046","cik":1156039,"company_name":"Elevance Health, Inc.","ticker":"ELV","form_type":"8-K","filed_at":"2026-05-13T20:07:56+00:00","items":["5.07"],"status":"ready","headline":"Elevance Health annual meeting: directors elected, exec pay approved, shareholder proposal defeated","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gail K. Boudreaux, Robert L. Dixon Jr., and Deanna D. Strable elected as directors for three-year terms.","Advisory vote on named executive officer compensation approved with 172.4M for vs 7.2M against.","Ratification of Ernst & Young as auditor for FY 2026 passed with 175.2M for, 19.1M against.","Shareholder proposal for independent study on banning corporate 527 political contributions defeated: 15.6M for, 162.9M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":84845337744.5227,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91570,"accession_number":"0001156039-26-000039","cik":1156039,"company_name":"Elevance Health, Inc.","ticker":"ELV","form_type":"8-K","filed_at":"2026-04-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Elevance Health Q1 adj EPS $12.58 beats; raises FY2026 adj EPS guidance to at least $26.75","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 operating revenue $49.5B (+1.5% YoY); diluted EPS $8.00, adjusted diluted EPS $12.58 (includes ~$1 non-recurring investment income).","Health Benefits segment revenue $42.5B (+2.6% YoY); operating margin 5.1% vs 5.4% YoY.","Carelon segment revenue $18.0B (+7.9% YoY); operating margin 5.9% vs 6.6% YoY.","Recorded $935M accrual for CMS matter and $129M business optimization charge; adjusted operating margin 6.5%.","FY2026 adjusted EPS guidance raised to at least $26.75; reaffirm operating cash flow at least $5.5B."],"consensus_eps_estimate":10.9301,"consensus_eps_actual":8.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":50181000000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":84845337744.5227,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101762,"accession_number":"0001156039-26-000024","cik":1156039,"company_name":"Elevance Health, Inc.","ticker":"ELV","form_type":"8-K","filed_at":"2026-03-10T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Elevance Health reaffirms FY2026 adj. EPS at least $25.50, benefit expense ratio ~90.2%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reaffirms adjusted shareholders' earnings for FY2026 at least $25.50 per diluted share.","Reaffirms 2026 benefit expense ratio guidance of 90.2% plus or minus 50 basis points.","Guidance includes impact of potential CMS sanctions suspending Medicare Advantage enrollment effective March 31, 2026 if not resolved.","Company cannot provide GAAP reconciliation due to uncertainty over financial payments to resolve CMS matter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":84845337744.5227,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101761,"accession_number":"0001156039-26-000022","cik":1156039,"company_name":"Elevance Health, Inc.","ticker":"ELV","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"CMS proposes sanctions suspending Elevance Medicare Advantage enrollment over risk adjustment data issues","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CMS notified Elevance of intent to impose sanctions suspending MA-PD enrollment and certain communications effective March 31, 2026 unless resolved.","Sanctions relate to alleged noncompliance with Medicare Advantage risk adjustment data submission requirements for dates of service prior to April 3, 2023.","Elevance revised practices in April 2023 following additional regulatory guidance; current MA-PD members' benefits and plans are unaffected.","Company is engaging with CMS and committed to addressing concerns cooperatively."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":84845337744.5227,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101760,"accession_number":"0001156039-26-000019","cik":1156039,"company_name":"Elevance Health, Inc.","ticker":"ELV","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"CFO Mark Kaye adds Carelon oversight; Haytaian transitions; FY2026 guidance reaffirmed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Peter Haytaian steps down as Carelon President effective May 4, 2026; will serve as Special Advisor through Dec 31, 2026.","CFO Mark Kaye expands role to oversee Carelon operations including pharmacy, behavioral, value-based care, and care delivery.","Felicia Norwood consolidates Commercial and Government Health Benefits under a single accountable structure.","FY2026 adjusted EPS guidance reaffirmed at least $25.50; reported EPS at least $22.30 (incl. $3.20 net unfavorable items).","Benefit expense ratio guidance reaffirmed at 90.2% +/- 50 bps for full year 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":84845337744.5227,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101759,"accession_number":"0001156039-26-000006","cik":1156039,"company_name":"Elevance Health, Inc.","ticker":"ELV","form_type":"8-K","filed_at":"2026-01-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Elevance Health Q4 adj. EPS $3.33 on higher medical costs; FY2026 adj. EPS guide $25.50, down from $30.29","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 GAAP diluted EPS $2.47; adjusted $3.33; operating revenue $49.3B (+10% YoY).","Full year 2025 GAAP EPS $25.21; adjusted $30.29; operating revenue $197.6B (+13% YoY).","Health Benefits segment Q4 adjusted operating loss of $0.2B; benefit expense ratio 93.5% (+110 bps YoY).","FY2026 guidance: GAAP EPS at least $22.30; adjusted EPS at least $25.50; targeting 12% adjusted EPS growth in 2027.","Returned $4.1B to shareholders in 2025; quarterly dividend raised to $1.72 per share."],"consensus_eps_estimate":3.128,"consensus_eps_actual":25.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":199125000000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":84845337744.5227,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118076,"accession_number":"0001156039-25-000142","cik":1156039,"company_name":"Elevance Health, Inc.","ticker":"ELV","form_type":"8-K","filed_at":"2025-12-10T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Elevance Health elects Amy Schulman as independent director effective Jan 12, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Amy Schulman, Managing Partner at Polaris Partners, joins Elevance Health board.","Appointed to Audit and Finance Committees; effective January 12, 2026.","Schulman also chairs Alnylam Pharmaceuticals board and is senior lecturer at Harvard Business School.","Board cites ongoing refreshment strategy; Schulman brings healthcare, governance, and investment expertise."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":84845337744.5227,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118075,"accession_number":"0001156039-25-000139","cik":1156039,"company_name":"Elevance Health, Inc.","ticker":"ELV","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Elevance Health reaffirms FY2025 EPS guidance of $24.70 ($30.00 adj.) and 90.0% benefit expense ratio","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Full-year 2025 GAAP EPS expected ~$24.70, including ~$5.30/sh net unfavorable items.","Adjusted EPS guidance unchanged at ~$30.00 per diluted share.","Full-year 2025 benefit expense ratio reaffirmed at approximately 90.0%.","Reaffirmation reflects current view on market conditions, operational performance, and regulatory landscape.","Guidance does not include adjustment items beyond those reported in Q3 2025 earnings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":84845337744.5227,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118074,"accession_number":"0001193125-25-244191","cik":1156039,"company_name":"Elevance Health, Inc.","ticker":"ELV","form_type":"8-K","filed_at":"2025-10-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Q3 revenue $50.1B (+12% YoY), GAAP EPS $5.32, adj. EPS $6.03; FY guidance reaffirmed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Health Benefits operating revenue $42.2B (+10% YoY), operating margin 1.4%, medical membership ~45.4M.","Carelon revenue $18.3B (+33% YoY), operating margin 4.2%; driven by acquisitions and pharmacy growth.","Benefit expense ratio 91.3% (up 180 bps YoY) on elevated Medicare Part D trend; operating expense ratio improved 130 bps to 10.5%.","Year-to-date operating cash flow $4.2B; Q3 share repurchases 2.9M shares at $303.48 avg price, $875M total.","Dividend of $1.71/share declared, payable Dec 19, 2025 to holders of record Dec 5, 2025."],"consensus_eps_estimate":4.9826,"consensus_eps_actual":22.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":149378000000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":84845337744.5227,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134523,"accession_number":"0001193125-25-203542","cik":1156039,"company_name":"Elevance Health, Inc.","ticker":"ELV","form_type":"8-K","filed_at":"2025-09-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Elevance Health closes $3B multi-tranche note offering; proceeds to refinance near-term debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $750M 4.000% notes due 2028, $750M 4.600% notes due 2032, $1,000M 5.000% notes due 2036, $500M 5.700% notes due 2055.","Net proceeds ~$2.973B after underwriting discounts and expenses.","Plans to use net proceeds to repay $400M 5.350% senior notes due 2025 and $500M 4.900% senior notes due 2026, plus general corporate purposes.","Notes are unsecured, rank pari passu; include change-of-control repurchase triggers at 101%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":84845337744.5227,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134522,"accession_number":"0001156039-25-000129","cik":1156039,"company_name":"Elevance Health, Inc.","ticker":"ELV","form_type":"8-K","filed_at":"2025-09-04T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Reaffirms full-year 2025 adjusted EPS guidance of $30.00 and benefit expense ratio of 90.0%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Reaffirms FY2025 GAAP EPS guidance of ~$24.10, including ~$5.90 net unfavorable items.","Reaffirms FY2025 adjusted EPS guidance of ~$30.00 per diluted share.","Reaffirms FY2025 benefit expense ratio guidance of approximately 90.0%.","Company officers to discuss outlook with investors over next several weeks."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":84845337744.5227,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134521,"accession_number":"0001156039-25-000118","cik":1156039,"company_name":"Elevance Health, Inc.","ticker":"ELV","form_type":"8-K","filed_at":"2025-07-28T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Elevance Health elects Steven H. Collis to board, effective Aug 1, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Steven H. Collis, Executive Chairman of Cencora, elected as independent director effective Aug 1, 2025.","Collis appointed to Audit and Finance Committees; qualifies as audit committee financial expert.","Collis served as Cencora (formerly AmerisourceBergen) CEO from 2011 to 2024, leading strategic transformation.","Board Chair Ramey Peru cites Collis's leadership and operational expertise to support Elevance's strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":84845337744.5227,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134520,"accession_number":"0001156039-25-000111","cik":1156039,"company_name":"Elevance Health, Inc.","ticker":"ELV","form_type":"8-K","filed_at":"2025-07-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Elevance Health cuts FY2025 adjusted EPS guidance to ~$30 on elevated medical costs","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Operating revenue $49.4B (+14.3% YoY); diluted EPS $7.72, adjusted diluted EPS $8.84.","Benefit expense ratio 88.9% (+260 bps) reflecting higher medical costs in Medicaid and ACA.","FY2025 GAAP EPS guidance ~$24.10; adjusted EPS guidance ~$30.00 (previously ~$35).","Health Benefits segment operating gain $1.6B vs $2.1B prior year; margin 3.8% vs 5.8%.","Returned $2.0B of capital to shareholders YTD; declared $1.71/quarter dividend payable 9/25/25."],"consensus_eps_estimate":9.0443,"consensus_eps_actual":17.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":98667000000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":84845337744.5227,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151367,"accession_number":"0001156039-25-000096","cik":1156039,"company_name":"Elevance Health, Inc.","ticker":"ELV","form_type":"8-K","filed_at":"2025-05-28T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Elevance reaffirms FY2025 adjusted EPS guidance of $34.15-$34.85","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FY2025 GAAP EPS guidance $28.30-$29.00, including ~$5.85 net unfavorable items.","Adjusted EPS guidance unchanged at $34.15-$34.85.","Benefit expense ratio guidance reaffirmed at 89.1% ± 50 bps.","Company expects 60% of adjusted EPS to be realized in first half of 2025.","Officers reiterate guidance during investor meetings this week."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":84845337744.5227,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151366,"accession_number":"0001156039-25-000065","cik":1156039,"company_name":"Elevance Health, Inc.","ticker":"ELV","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Elevance Health shareholders elect directors, approve say-on-pay, reject DEI proposal","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Directors DeVore (185.8M for), Jallal (180.8M for), Schneider (184.6M for) elected to three-year terms.","Advisory vote on executive compensation approved with 173.96M for vs. 15.52M against.","Ratification of Ernst & Young LLP as auditor for 2025 passed with 178.09M for.","Shareholder DEI effectiveness report proposal defeated: 160.69M against, 26.24M for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":84845337744.5227,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151365,"accession_number":"0001156039-25-000056","cik":1156039,"company_name":"Elevance Health, Inc.","ticker":"ELV","form_type":"8-K","filed_at":"2025-04-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Elevance Health Q1 2025 revenue $48.8B (+15.4% YoY); adj. diluted EPS $11.97; reaffirms FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Operating revenue $48.8B (+15.4% YoY); diluted GAAP EPS $9.61, adjusted diluted EPS $11.97.","Benefit expense ratio 86.4% (+80 bps YoY); operating expense ratio 10.9% (-70 bps).","Health Benefits segment op. revenue $41.4B, op. gain $2.2B; Carelon op. revenue $16.7B, op. gain $1.1B.","Medical membership ~45.8M (+99K from year-end); returned $1.3B capital via buybacks & dividends.","Reaffirmed FY 2025 adjusted diluted EPS guidance $34.15-$34.85; Q2 dividend $1.71/share declared."],"consensus_eps_estimate":null,"consensus_eps_actual":9.61,"consensus_revenue_estimate":null,"consensus_revenue_actual":48891000000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":84845337744.5227,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151364,"accession_number":"0001156039-25-000051","cik":1156039,"company_name":"Elevance Health, Inc.","ticker":"ELV","form_type":"8-K","filed_at":"2025-04-17T23:59:59+00:00","items":["2.02","7.01"],"status":"ready","headline":"Elevance Health pre-announces Q1 2025 adjusted EPS of $11.97; reaffirms FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 GAAP EPS of $9.61, includes $2.36/share net unfavorable items; adjusted EPS $11.97.","Medical cost trends, including Medicare Advantage, in line with expectations during Q1.","Reaffirms FY 2025 adjusted EPS guidance of $34.15–$34.85; Medicare Advantage membership 2,200–2,250k.","Full Q1 results and outlook details to be released on April 22, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":9.61,"consensus_revenue_estimate":null,"consensus_revenue_actual":48891000000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":84845337744.5227,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170262,"accession_number":"0001193125-25-050889","cik":1156039,"company_name":"Elevance Health, Inc.","ticker":"ELV","form_type":"8-K","filed_at":"2025-03-10T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Elevance Health reaffirms FY 2025 adjusted EPS guidance of $34.15-$34.85","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reaffirms 2025 shareholders' earnings per diluted share of $30.40-$31.10, including ~$3.75 net unfavorable items.","Adjusted shareholders' earnings guidance unchanged at $34.15-$34.85 per diluted share.","Expects 2025 year-end total medical enrollment consistent with prior guidance; Medicare Advantage members 2.2-2.25 million.","Management to reiterate these projections in investor meetings over coming weeks."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":84845337744.5227,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170261,"accession_number":"0001156039-25-000007","cik":1156039,"company_name":"Elevance Health, Inc.","ticker":"ELV","form_type":"8-K","filed_at":"2025-01-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Elevance Health Q4 2024 adjusted EPS $3.84, FY 2025 guidance $34.15-$34.85; dividend raised 5% to $1.71","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 operating revenue $45.0B (+6% YoY); FY revenue $175.2B (+3%).","Q4 GAAP EPS $1.81; adjusted EPS $3.84. FY GAAP EPS $25.68; adjusted EPS $33.04.","Health Benefits Q4 operating margin 0.6% (down from 2.1% YoY) on higher Medicaid cost trend.","Carelon Q4 adjusted operating margin 5.3% (up from 4.8% YoY); FY adjusted margin 5.8%.","FY 2025 adjusted EPS guidance $34.15-$34.85; dividend raised 5% to $1.71, payable 3/25/25."],"consensus_eps_estimate":null,"consensus_eps_actual":25.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":177011000000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":84845337744.5227,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187272,"accession_number":"0001193125-24-248691","cik":1156039,"company_name":"Elevance Health, Inc.","ticker":"ELV","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Elevance Health closes $5.2B multi-tranche notes offering; proceeds for general corporate purposes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $5.2B aggregate principal across six series: 2026 (4.500%), 2030 (4.750%), 2031 (4.950%), 2035 (5.200%), 2055 (5.700%), 2064 (5.850%).","Net proceeds of approximately $5.138B after underwriting discounts and expenses.","Proceeds intended for working capital, acquisitions, debt repayment, and share repurchases.","Notes issued under existing indenture; underwriters include Citigroup, Morgan Stanley, Wells Fargo."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":84845337744.5227,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187271,"accession_number":"0001156039-24-000119","cik":1156039,"company_name":"Elevance Health, Inc.","ticker":"ELV","form_type":"8-K","filed_at":"2024-10-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Elevance Health Q3 adjusted EPS $8.37; FY2024 guidance cut to ~$33.00","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2024 operating revenue $44.7B, up $2.2B YoY; diluted EPS $4.36 GAAP, adjusted $8.37.","Benefit expense ratio 89.5%, up 270 bps driven by Medicaid rate-acuity mismatch; operating margin 3.1% (adj 5.3%).","Medical membership ~45.8M, down 1.5M (3%) due to Medicaid attrition and footprint adjustments.","Board authorized $8.0B increase to share repurchase program; Q4 dividend $1.63/share declared.","FY2024 GAAP EPS guidance ~$26.50, adjusted EPS ~$33.00, reflecting Medicaid headwinds."],"consensus_eps_estimate":null,"consensus_eps_actual":23.81,"consensus_revenue_estimate":null,"consensus_revenue_actual":131569000000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":84845337744.5227,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203782,"accession_number":"0001156039-24-000101","cik":1156039,"company_name":"Elevance Health, Inc.","ticker":"ELV","form_type":"8-K","filed_at":"2024-07-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Elevance Health Q2 diluted EPS $9.85 (+26% YoY); revenue $43.2B, down $0.2B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Adjusted diluted EPS $10.12 (+12% YoY); GAAP EPS at least $34.05 for FY2024, adjusted at least $37.20.","Health Benefits revenue $37.2B (-2%); Carelon revenue $13.3B (+10%) on risk-based service growth.","Medical membership 45.8M, down 5% YoY due to Medicaid redeterminations; partly offset by ACA growth.","Benefit expense ratio improved 10 bps to 86.3%; operating expense ratio increased to 11.7%.","Q3 dividend $1.63/share declared, payable Sept 25, 2024; $3.2B share repurchase authorization remaining."],"consensus_eps_estimate":null,"consensus_eps_actual":19.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":86463000000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":84845337744.5227,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220358,"accession_number":"0001156039-24-000093","cik":1156039,"company_name":"Elevance Health, Inc.","ticker":"ELV","form_type":"8-K","filed_at":"2024-06-12T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Elevance Health reaffirms FY2024 net income >$34.05, adjusted >$37.20 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net income guidance for FY2024 greater than $34.05 per diluted share including approximately $3.15 per share of net unfavorable items.","Adjusted net income guidance greater than $37.20 per diluted share, excluding the unfavorable items.","Guidance does not include any adjustment items beyond those reported in Q1 2024 earnings release.","Company officers reaffirming guidance during investor meetings over the next several weeks."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":84845337744.5227,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220357,"accession_number":"0001193125-24-150440","cik":1156039,"company_name":"Elevance Health, Inc.","ticker":"ELV","form_type":"8-K","filed_at":"2024-05-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Elevance Health closes $2.6B senior notes offering in three tranches","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $600M 5.150% notes due 2029, $1B 5.375% notes due 2034, $1B 5.650% notes due 2054.","Net proceeds of approximately $2.5724B after underwriting discounts and expenses.","Proceeds to be used for working capital, acquisitions, debt repayment, or share repurchases.","Interest payable semi-annually on June 15 and December 15, starting December 15, 2024.","Notes redeemable at make-whole premiums before par call dates; subject to change-of-control put at 101%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":84845337744.5227,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220356,"accession_number":"0001156039-24-000069","cik":1156039,"company_name":"Elevance Health, Inc.","ticker":"ELV","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Elevance Health shareholders elect directors, approve executive pay, ratify E&Y, reject political spending proposal","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Lewis Hay, III, Antonio F. Neri, and Ramiro G. Peru were elected as directors for three-year terms with over 183 million votes each.","Advisory vote on executive compensation approved with 179,754,212 for and 15,863,613 against.","Ratification of Ernst & Young LLP as independent auditor for 2024 passed with 186,378,524 votes for.","Shareholder proposal on annual political activity reporting rejected with only 9,977,190 votes in favor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":84845337744.5227,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220355,"accession_number":"0001193125-24-099824","cik":1156039,"company_name":"Elevance Health, Inc.","ticker":"ELV","form_type":"8-K","filed_at":"2024-04-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Elevance Health Q1 diluted EPS $9.59 (+15.5%); raises FY2024 adj. EPS guidance to >$37.20","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 operating revenue $42.3B (+0.9% YoY); diluted EPS $9.59 (+15.5%); adjusted diluted EPS $10.64 (+12.5%).","Benefit expense ratio 85.6%, improving 20 bps; operating margin 7.1% vs 6.8% YoY.","Medical membership 46.2M, down 1.9M YoY due to Medicaid attrition, partially offset by commercial growth.","Carelon revenue $12.1B (+5%); operating gain $0.8B (+10%).","FY2024 guidance raised: diluted EPS >$34.05, adjusted >$37.20; strategic partnership with CD&R for primary care."],"consensus_eps_estimate":null,"consensus_eps_actual":9.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":42577000000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":84845337744.5227,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}